Table 1.
Topotecan SCLC trials included in an integrated analysis
| Study | Phase | Patientsa, n |
|---|---|---|
| Ardizzoni et al (1997) | II | 101 |
| Eckardt et al (1996) | II | 99 |
| von Pawel et al (2001) | II | 54b |
| Depierre et al (1997) | II | 119 |
| von Pawel et al (1999) | III | 107 |
a
Note: Patients from all trials received the US Food and Drug Administration approved dose and schedule of topotecan (1.5 mg/m2 on days 1 to 5 of a 21-day cycle)
b
Number of patients in the intravenous arm of a randomized study who were treated with the US Food and Drug Administration-approved dose of topotecan. Adapted with permission from Treat et al (2004).
Abbreviations: SCLC, Small cell lung cancer.